Your search
Results 415 resources
-
Introduction: Respiratory viral infections (RVI) in lung transplant recipients (LTR) have variably been associated with rejection and chronic lung allograft dysfunction. Our center has used systemic corticosteroids to treat outpatient RVI in some cases, but evidence is limited. We reviewed all adult LTR diagnosed with outpatient RVI January 2017 to December 2019. The primary outcome was recovery of lung function (forced expiratory volume in 1 s [FEV1]) at next stable visit between 1 and 12...
-
Background There is scarce information on the natural kinetics of cytomegalovirus (CMV) DNAemia and dynamics of CMV-specific T-cell reconstitution in allogeneic hematopoietic transplant recipients (allo-HSCT) undergoing letermovir (LMV) prophylaxis. Methods Twelve adult CMV-seropositive high-risk recipients (median age, 53 years; 9 males/3 females) undergoing LMV prophylaxis and 13 non-LMV allo-HSCT controls (median age, 58 years; 7 males/6 females) were included. CMV DNAemia in plasma was...
-
Background Decisions to transplant organs from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid test-positive (NAT+) donors must balance risk of donor-derived transmission events (DDTE) with the scarcity of available organs. Methods Organ Procurement and Transplantation Network (OPTN) data were used to compare organ utilization and recipient outcomes between SARS-CoV-2 NAT+ and NAT– donors. NAT+ was defined by either a positive upper or lower respiratory tract (LRT)...
-
Background The optimal number of doses as well as the role for measurement of postvaccination titers after measles, mumps, rubella (MMR) vaccination in adult hematopoietic cell transplantation (HCT) recipients remains unknown. Methods In the present study, we assessed humoral immunity against measles, mumps and rubella before and after MMR vaccination in 187 adults who received at least one dose of the MMR vaccine after HCT. Results Among those with baseline titers, posttransplant...
-
Letermovir is a relatively new antiviral for prophylaxis against cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT). CMV-seropositive HCT recipients who received letermovir prophylaxis from 2018 to 2020 at our center were evaluated for letermovir resistance and breakthrough CMV reactivation. Two-hundred twenty-six letermovir recipients were identified and 7/15 (47%) with CMV DNAemia ≥200 IU/mL were successfully genotyped for UL56 resistance. A single C325Y...
-
Abstract Objectives The gastrointestinal (GI) tract is a major human adenovirus (HAdV) replication site in patients undergoing hematopoietic stem cell transplantation (HSCT), yet the prevalence and correlates of HAdV GI infection in this setting have remained poorly recognized, especially among adult HSCT recipients. Design or methods We retrospectively studied the prevalence and risk...
-
Background. Previous studies indicate an association between reduced absolute lymphocyte count (ALC) and cytomegalovirus (CMV) infection after solid organ transplantation and have therefore highlighted the potential of ALC as a simple tool to predict CMV infection in transplant patients. This study aimed to examine the utility of ALC as a valuable marker for CMV infection in heart transplant patients. Methods. Clinical information and ALC data of all adult patients...
-
CDC reviewed COVID-19 rebound studies among patients who
-
To determine the effect of donor hepatitis C virus (HCV) infection on kidney transplant (KT) outcomes in the era of direct-acting antiviral (DAA) medications, we examined 68,087 HCV-negative KT recipients from a deceased donor between March 2015 and May 2021. A Cox regression analysis was used to estimate adjusted hazard ratios (aHRs) of KT failure, incorporating inverse probability of treatment weighting to control for patient selection to receive an HCV-positive kidney (either nucleic acid...
-
Background Transplant and hematologic malignancy patients have high Coronavirus disease 2019 (COVID-19) mortality and impaired vaccination responses. Omicron variant evades several monoclonal antibodies previously used in immunocompromised patients. Polyclonal COVID-19 convalescent plasma (CCP) may provide broader neutralizing capacity against new variants at high titers. Vaccination increases severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) titer in convalescent donors. Methods...
-
Background. Although mammalian target of rapamycin inhibitors (mTORi) are associated with a lower incidence of the first episode of cytomegalovirus (CMV) infection/disease in kidney transplant recipients receiving calcineurin inhibitors (CNIs), the efficacy and safety of the conversion from the antimetabolite to an mTORi for the prevention of CMV recurrence are unknown. Methods. In this single-center prospective randomized...
-
Human herpesvirus 6 (HHV-6) reactivation is common after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and is associated with higher mortality and increased transplantation-related complications. We hypothesized that preemptive treatment with a short course of foscarnet at a lower cutpoint of plasma HHV-6 viral load would be effective in treating early HHV-6 reactivation, preventing complications and precluding hospitalization of these patients. We reviewed outcomes of adult...
-
Abstract Objective and Background BK virus‐associated hemorrhagic cystitis (BKV‐HC) is an intractable complication leading to higher mortality and prolonged hospitalization among allogeneic hematopoietic stem cell transplantation (allo‐HCT) recipients. Therefore, identifying the potential risk factors of BKV‐HC after allo‐HCT is crucial to improve prognosis and for early prevention. However, the risk factors for BKV‐HC remain debatable. Therefore,...
-
Preventing viral infections at an early stage is a key strategy of successfully improving transplant outcomes. Preemptive therapy and prophylaxis using antiviral agents have been used successfully to prevent clinically significant viral infections in hematopoietic cell transplant (HCT) recipients. Major progress has been made over the past decades in preventing viral infections through a better understanding of the biology and risk factors as well as the introduction of novel antiviral...
Filter by our tag
GUIDELINES
- AASLD Guidelines (2)
- AST Guidelines 2019 (13)
- ASTCT Guidelines (7)
- ECIL Guidelines (8)
- ESCMID Guidelines (3)
- IDSA Guidelines (8)
- TTS Guidelines (1)
TEXTBOOKS
CORE CURRICULUM
ORGANISMS
-
VIRUSES
- Adenovirus (17)
- Arboviruses (7)
-
CMV
(121)
- Cell-Mediated Immunity Assays (11)
- Clinical (55)
- Cytotoxic T-Lymphocytes (1)
- Epidemiology and Risk Factors (15)
- Letermovir (26)
- Maribavir (17)
- Preemptive Therapy (7)
-
COVID-19
(45)
- Diagnosis (3)
- Fungal superinfection (2)
- GUIDELINES (9)
- Infection Prevention (3)
- Positive Donors (6)
- Positive Recipients (5)
- Treatments (18)
- Vaccination (8)
- Hepatitis A (2)
- Hepatitis B (27)
- Hepatitis C (31)
- Hepatitis D (5)
- Hepatitis E (5)
- HHV-6 (24)
- HHV-8 (4)
- HIV (31)
- HPV (5)
- HSV (4)
- Influenza (17)
- Measles (22)
- Mpox (6)
- Norovirus (8)
- Parvovirus B19 (3)
- Polyomaviruses (32)
- Respiratory Viruses (32)
- RSV (18)
- VZV (17)
- WNV (2)
-
BACTERIA
(1)
- C. difficile (1)
-
FUNGI
(2)
- Aspergillus (2)
- Candida (1)
- Mucormycosis (1)
- Rarer Fungi (1)
DRUGS AND THERAPIES
- Antibiotics (1)
- Antifungals (1)
- Antivirals (8)
- Cytotoxic T-lymphocyte therapy (4)
- Fecal Microbiota Transplantation (1)
- Stewardship (2)
PREVENTION
- Safe Living (1)
- Travel (2)
- Vaccination (27)
SYNDROMES AND CONDITIONS
- Diarrhea (5)
SOLID ORGANS AND MCSS
HEME-ONC AND CELLULAR THERAPIES
- Biologics (8)
- BMT Basics (1)
- BMT Guidelines (8)
- BMT-specific ID (35)
- CAR-T (4)
- Heme-onc prophylaxis (3)
- Neutropenia (1)
- PEDIATRIC (9)
- PTLD (4)
- TK inhibitors (1)
PATIENT EDUCATION
- COVID-19 (1)
- Selected Infections (1)
ATC 2024 Top Papers in TID
- VIRUSES (7)